JP4408612B2 - New acetylene compounds - Google Patents
New acetylene compounds Download PDFInfo
- Publication number
- JP4408612B2 JP4408612B2 JP2002245569A JP2002245569A JP4408612B2 JP 4408612 B2 JP4408612 B2 JP 4408612B2 JP 2002245569 A JP2002245569 A JP 2002245569A JP 2002245569 A JP2002245569 A JP 2002245569A JP 4408612 B2 JP4408612 B2 JP 4408612B2
- Authority
- JP
- Japan
- Prior art keywords
- compounds
- bidens
- methanol
- group
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 21
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 229940126904 hypoglycaemic agent Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- -1 β-D-glucopyranosyl Chemical group 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 241000196324 Embryophyta Species 0.000 description 10
- 244000104272 Bidens pilosa Species 0.000 description 9
- 235000010662 Bidens pilosa Nutrition 0.000 description 9
- 239000011734 sodium Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical group O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 241000208838 Asteraceae Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000143476 Bidens Species 0.000 description 2
- 241001195282 Bidens biternata Species 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000004035 Cryptotaenia japonica Nutrition 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 241000209504 Poaceae Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 102000007641 Trefoil Factors Human genes 0.000 description 2
- 235000015724 Trifolium pratense Nutrition 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000554155 Andes Species 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000498892 Bidens cernua Species 0.000 description 1
- 241000842326 Bidens parviflora Species 0.000 description 1
- 241000390822 Bidens radiata Species 0.000 description 1
- 240000004082 Bidens tripartita Species 0.000 description 1
- 235000000621 Bidens tripartita Nutrition 0.000 description 1
- 238000011735 C3H mouse Methods 0.000 description 1
- 241000206601 Carnobacterium mobile Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000288297 Danthonia decumbens Species 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 244000081757 Phalaris arundinacea Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 244000000053 intestinal parasite Species 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【0001】
【産業上の利用分野】
本発明は血糖低下及び抗炎症作用を有する保健上有用な化合物に関する。
【従来の技術】
【0002】
糖尿病は生活習慣病の一つであり患者は予備軍を含めると日本に1470万人とも言われる大衆病である。また炎症は、ウイルスや細菌による感染を始め外傷、打撲などの手術などの侵襲に対する生体防御反応の一環として起こる正常反応であるが一方では発熱・疼痛・腫脹・機能障害を伴い治療上これを抑制する必要がしばしば起こってくる。
【0003】
いずれもこれまで天然物からの検索や合成医薬品として血糖低下作用や抗炎症作用に優れた薬物が多数知られており、また実用にも供されているがより優れたものを求める探索努力が各方面において地道に継続されている。
【発明が解決しようとする課題及び課題を解決するための手段】
【0004】
発明者等は、安全性に優れ、かつこれらの目的に適した植物を対象に探索を進め、既に民間伝承薬として広く利用されているセンダングサ属の植物から血糖低下作用や抗炎症作用に優れた化合物を検索することによって、新しい血糖降下剤や抗炎症剤を提供しようとするものである。
【0005】
本発明の化合物は、キク科センダングサ属植物のBidens pilosaから発見された文献未載の新規化合物である。Bidens pilosaで代表されるキク科センダングサ属植物は、特願2000−105559に詳述したように、種類も多岐に亘り互いに交配するので変種も多く、植物学上も混乱が見られ、学名、和名、漢名、の対応も交錯していて同定することは極めて困難であるが、本発明で用いられるセンダングサ属植物は以下に掲げるものを包含する。
【0006】
Bidens pilosa L.(コセンダングサ、コシロノセンダングサ、咸豊草)
Bidens pilosa L.var.minor(Blume)Sherff(シロバナセンダングサ、シロノセンダングサ、コシロノセンダングサ、コセンダングサ、咸豊草)
Bidens pilosa L.var.bisetosa Ohtani et Suzuki(アワユキセンダングサ)
Bidens pilosa L.f.decumbens Scherff(ハイアワユキセンダングサ)
Bidens pilosa L.var.radiata Scherff(タチアワユキセンダングサ、ハイアワユキセンダングサを含むこともある)
Bidens pilosa L.var.radiata Schultz Bipontinus(シロノセンダングサ、オオバナノセンダングサ)
Bidens biternata Lour.Merrill et Scherff(センダングサ)
Bidens bipinnata L.(コバノセンダングサ、センダングサ)
Bidens cernua L.(ヤナギタウコギ)
Bidens frondosa L.(アメリカセンダングサ、セイタカタウコギ)
Bidens parviflora Willd(ホソバノセンダングサ)
Bidens radiata Thuill.var.pinnatifida (Turcz.)Kitamura(エゾノタウコギ)
Bidens tripartita L.(タウコギ)
【0007】
この植物は中国・台湾では主に咸豊草と呼ばれるが異名も多く、同治草、鬼針草、三葉鬼針草、三葉刺針草、刺針草、婆婆針草、白花婆婆針、蝦箝草、符因草、符因頭、赤査某、金盞銀盤、含風草、南風草、蝦公鋏、羞査某仔等の名があり、それぞれがどの学名に相当するのかは明らかでない。
【0008】
花はキク科特有の形で、白色または黄色の丸みのある花弁のような舌状花が数個、中央には黄褐色の管状花が多数集合している。中には舌状花を欠くものもある。茎は四角で薄紫に着色した節がある。3つまたは5つに羽状に分かれた葉には柄があり、縁にはぎざぎざがあって対生しているものが多い。
【0009】
日本では本州の暖地以南で見られ、台湾、中国ないし世界の亜熱帯ないし熱帯各地に分布し、草丈は25cm〜約1mにもなり、通常一年草であるが温暖な気候条件に恵まれると越冬し、花は一年中次々と咲く。動物や人の衣服に付いて運ばれる黒褐色の種子の上部に逆棘のある針があり、針の数も交配のため一定しないものが多い。中国では鬼針草属と呼ばれている。
【0010】
センダングサ属植物とくにBidens pilosaは古来伝承薬として経験的に、全草が糖尿病や炎症性疾患、各種消化器病、各種感染症、リウマチ、等の治療に、アフリカ、中南米、アジア等世界の熱帯〜温帯地域で広く使われてきた。例えば台湾では急・慢性虫垂炎、腎炎、胃腸炎、下痢、インフルエンザ、咽頭炎、歯痛、肝炎、十二指腸炎に広く用いられ、肝臓の保護作用があるとされている。アフリカでは傷の治療や重症悪阻(おそ)、胃痛、便秘、腸内寄生虫、赤痢、下痢、腹痛等に使われてきた。葉の搾汁は火傷や結膜炎、耳炎、さらに止血剤にも用いるという。磨砕した汁や根の料理はマラリアに効くと言われ、ズールー族では新芽を噛んでリウマチの薬としている。中国では腸炎、桿菌赤痢、咽頭炎に使われ、この植物を砕きあるいは煎じて傷の治療や慢性潰瘍に使用される。中央アメリカの島々では搾汁を目薬に、ベネズエラやブラジルでは潰瘍に、ボリビアのアンデスでは血圧を下げるのに使う。また利尿や胆汁分泌促進、風疹や猩猴熱の解熱にも用いる。
【0011】
発明者等はこれほど使用経験の豊富な、従って安全性に優れた本植物のエキスにつき、ヒトの糖尿病、高脂血症、アトピー性皮膚炎、肝炎、下肢に生じる難治性夏季潰瘍、等に特に効果を認め、また動物実験によっても繰返しその効果を裏付ける結果を得たことから、本植物に含まれる各種化合物を分画し、その単離精製を試み3種の新規化合物の発見に至ったものである。
【0012】
【測定用機器】
紫外部スペクトル:島津分光光度計UV12008
赤外部スペクトル:Perkin−Elmer1720X−FTIE分光計
MSスペクトル:日立M−80分光計
NMRスペクトル:Varian Mercury 300、及びunityInova−500(溶媒:CDCl3 、CD3 OD、及びpyridine−d5 、内部標準としてテトラメチルシランを用いたδスケール上)
【0013】
【実験例1】
原料からの分画単離
沖縄県宮古島で自生するBidens pilosa L.var.radiata (和名タチアワユキセンダングサ)を圃場で無農薬栽培し、刈り取った地上部を洗浄、裁断、蒸煮、圧潰、揉解、乾燥工程を経たものを原料とした。原料500gを3.5Lの水で3回、還流下に抽出し、600mLのダイヤイオンHP−20カラムに通して水で洗浄、カラムは50%メタノール、次いでメタノールで溶出した。溶出液の半分を70gのODSカラムに吸着、メタノール/水のメタノールの濃度を順次高めて50%メタノールで十分溶出し、最後にメタノールで溶出した画分を次の実験に供した。
【0014】
【実験例2】
逆相高速液体クロマトグラフィー
カラム:Cosmosil 5ph[5μ、1.0×25cm]、カラム温度30℃
移動相:CH3 CN−1%AcOH[10.5%−60%]、50分、linear gradient、流速2mL/min
検出:UV254nm
得られたHPLCの各ピークをさらにHPLCにかけて精製し、単離した成分の各種スペクトルデータや分解反応生成物の解析から化合物を同定、その構造を決定した。
【0015】
実験例2の結果、A、B、C、A´、B´、C´の化合物が構造決定された。その構造式を図1に示す。
【図1】
得られた化合物の構造式
【0016】
この内、A、B、Cは文献未載の新規化合物で、その1H−及び13C−NMRデータは表1のとおりである。
【表1】
化合物A、B、及びCの1H−及び13C−NMRデータ
【0017】
これらの化合物のNMR以外の特性データは次のとおりである。
【0018】
A:1,2-dihydroxy-5(E)-tridecene-7,9,11-triyne-1-Ο-malony-2-Ο-β-D-glucopyranoside(15-1-Ο-malonate).C22H26O10.SI-MS m/z:451(M+H)+,473(M+Na)+.
【0019】
A-methyl ester:C23H28O10.SI-MS m/z:487(M+Na)+,HR-SI-MS m/z:487.1574(M+Na)+,error:-0.4 m.m.u.[α]D+5.1゜(c=0.19,MeOH).IR(KBr)cm-1:3588,3424(OH),2225(C≡C),1736(COOR),1077,1029(C-O-C).UVλmax(MeOH)nm(logε):329.5(3.75),307.0(3.88),289.0(3.81),272.0(3.59),257.0(3.40),241.0(4.64),234.0(4.62),210.5(4.32).1H-NMRと13C-NMRのシグナルはこの構造と合理的に整合する。
【0020】
B:trideca-5,7,9,11-tetrayn-1,2-diol-1-Ο-malonyl-2-Ο-β-D-glucopyranoside(16-1-Ο-malonate).C22H24O10.SI-MS m/z:471(M+Na)+,487(M+K)+.
【0021】
B-methyl ester:C23H26O10.SI-MS m/z:485(M+Na)+,HR-SI-MS m/z:485.1421(M+Na)+,error:-0.1 m.m.u.[α]D+2.5゜(c=0.10,MeOH).IR(KBr)cm-1:3540,3436(OH),2229(C≡C),1729(COOR),1070,1035(C-O-C).UVλmax(MeOH)nm:329.0(3.45),308.0(3.58),289.0(3.56),273.0(3.47),235.5(4.77),225.0(4.70),215.0(4.47).1H-NMRと13C-NMRのシグナルはこの構造と合理的に整合する。
【0022】
C:tetradeca-6(E)-en-8,10,12-triyn-1,3-diol-1-Ο-malonyl-3-Ο-β-D-glucopyranoside(17-3-Ο-malonate).C23H28O10.SI-MS m/z:465(M+H)+,487(M+Na)+,HR-SI-MS m/z:465.1765(M+H)+,error:0.6 m.m.u.[α]D-28.7゜(c=0.29, MeOH).IR(KBr)cm-1:3446(OH),2223(C≡C),1728(COOH,COOR),1077,1029(C-O-C).UVλmax(MeOH)nm(logε):329.5(3.78),308.0(3.91),289.0(3.86),272.5(3.65),242.0(4.63),233.0(4.58),210.5(4.32).
【0023】
C-methyl ester:C24H30O10.SI-MS m/z:479(M+H)+,501(M+Na)+,HR-SI-MS m/z:479.1917(M+H)+,error:-0.2 m.m.u.[α]D-20.2゜(c=0.25,MeOH).IR(KBr)cm-1:3587,3567,3523(OH),2223(C≡C),1737(COOR),1078,1025(C-O-C).UVλmax(MeOH)nm(logε):329.5(3.83),308.0(3.97),289.0(3.90),272.5(3.70),257.5(2.50),242.0(4.63),232.0(4.61),210.0(4.39).1H-NMRと13C-NMRのシグナルはこの構造と合理的に整合する。
【0024】
【活性評価】
A、B、Cの化合物は、Rosa P.Ubillas et al.[Plant Med.66,82(2000)]が血糖を有意に低下させたと報告した化合物や、Rachel L.C.Pereila et al.[Immunopharmacology 43,31(1999)]が抗炎症効果を裏付けると報告した化合物と構造上極めて近いことから、Bidens pilosa L.の血糖低下作用や抗炎症作用を支える化合物群の一つであることは間違いないことと考えられる。
【0025】
【実施例1】
調製用高速液体クロマトグラフィー装置を用いて実験例1、2と同様の条件で得られた化合物A、B、Cの各画分から減圧濃縮によってメタノールを除き動物実験に供した。4週齢の雄C3Hマウスを対照群、ストレプトゾトシン(STZ)群、試験群4群の各群3匹、計18匹用意し、STZ群と試験群には体重kgあたりSTZ150mgを初日と翌日に腹腔内注射した。対照群とSTZ群は標準飼料を、試験群(A〜C)は標準飼料に上記A、B、Cの画分を、試験群(画分)は実験例1の最後のメタノール溶出画分(減圧下メタノールを除去)を、それぞれ原料(ビデンス・ピローサ加工乾燥物)に換算してマウス体重1kgあたり30g程度の摂取量になるよう混入して自由に摂取させた。2週間後、各群の血糖を測定した所、各群平均値で対照群213、STZ群683、試験群(A)516、試験群(B)476、試験群(C)498、試験群(画分)390mg/dLで、いずれも有意差が認められた。
【0026】
【実施例2】
ボランティア女性3人の左右上腕内側部それぞれ5カ所に、ラウリル硫酸ソーダ10%水溶液を染み込ませたカットバンを5時間貼って発赤を起こさせ、これを除去清拭して後、1カ所は市販の日焼け用クリーム、1カ所は実験例1の最後のメタノール溶出画分、あとの3カ所は実施例1で得た化合物A、B、Cの画分を染み込ませたカットバンを貼って24時間後、48時間後、72時間後に観察したところ、市販の日焼け用クリームは発赤が次第に薄くなるものの最後まで消えなかったが、実験例1のメタノール溶出画分及び化合物A、B、Cの画分ではいずれも1日で発赤が消失していた。すなわち、かなり強力な抗炎症性を示した。[0001]
[Industrial application fields]
The present invention relates to health-useful compounds having hypoglycemic and anti-inflammatory effects.
[Prior art]
[0002]
Diabetes is one of the lifestyle-related diseases, and the patient is a popular disease that is said to have 14.7 million people in Japan including the reserve army. Inflammation is a normal reaction that occurs as part of the body's defense response to invasion, such as infections such as viruses and bacteria, as well as injuries such as trauma and bruises, but it is suppressed therapeutically with fever, pain, swelling, and functional impairment. There is often a need to happen.
[0003]
All of them have been known from the search for natural products and synthetic drugs, and many drugs with excellent hypoglycemic and anti-inflammatory effects have been known. Continues steady in the direction.
SUMMARY OF THE INVENTION Problems to be Solved by the Invention and Means for Solving the Problems
[0004]
The inventors proceeded with the search for plants that are excellent in safety and suitable for these purposes, and were excellent in hypoglycemic action and anti-inflammatory action from plants of the genus Sendangsa already widely used as folklore medicines. By searching for compounds, we intend to provide new hypoglycemic and anti-inflammatory agents.
[0005]
The compound of the present invention is a novel compound that has not been described in the literature and was discovered from Bidens piosa of the Asteraceae family Sendungusa. As described in detail in Japanese Patent Application No. 2000-105559, Asteraceae plants represented by Bidens pilosa are crossed with each other in a wide variety and have many varieties. Although the correspondence between names and Chinese names is also mixed and identification is extremely difficult, the plants of the genus Sendangusa used in the present invention include those listed below.
[0006]
Bidens pilosa L. (Kosendangusa, Koshirono Sendangusa, Sakai Toyokusa)
Bidens pilosa L. var. minor (Blume) Shelf (Shirobana Sendangsa, Silono Sendangsa, Koshiro No Sendangsa, Kosen Dangusa, Sakai Toyokusa)
Bidens pilosa L. var. biseosa Ohtani et Suzuki ( Awayukisendangusa )
Bidens pilosa L. f. decumbens Scherff
Bidens pilosa L. var. radiata Scherff (Tachiawayukisendangusa, may also include Hiawayukisendangusa)
Bidens pilosa L. var. radiata Schultz Bipontinus (Shirono Sendangusa)
Bidens biternata Lour. Merrill et Scherff (Sendangsa)
Bidens bipinnata L. (Kobano Sendangsa, Sendangsa)
Bidens cernua L. (Yanagi Taukogi)
Bidens frontosa L. (American Sendangsa, Seitakatakogi)
Bidens parviflora Wild
Bidens radiata Thuill. var. pinnatifida (Turcz.) Kitamura (Ezonotaukougi)
Bidens tripartita L. (Taukogi)
[0007]
In China and Taiwan, this plant is mainly called 咸咸 草, but there are many synonyms, such as Oji grass, Oni grass, Trefoil needles, Trefoil needles, stab grasses, Acupuncture grasses, White flowers 婆婆 needles, Reed grass There are names such as, Inaba, Nobuno, Akaban, Jinbao Ginban, Fengwei, Nanfugrass, Gong Koan, and the puppet, and it is not clear which scientific name each corresponds to.
[0008]
The flower has a unique shape of the Asteraceae, with several tongue-like flowers like white or yellow round petals and many yellow-brown tubular flowers in the center. Some lack tongue-like flowers. The stem has square and light purple colored nodes. The leaves that are divided into three or five feathers have a pattern, and the edges have jagged edges, often facing each other.
[0009]
In Japan, it is found in the southern part of Honshu, and is distributed in Taiwan, China, the world's subtropics and tropics, and the plant height ranges from 25cm to about 1m. The flowers bloom one after the other. There are needles with inverted spines on the top of dark brown seeds carried on animal and human clothes, and the number of needles is often not constant due to mating. In China, it is called the Genus Genus.
[0010]
Sendungusa plants, especially Bidens pilosa, have been empirically used as a traditional remedy. The whole plant is used for the treatment of diabetes, inflammatory diseases, various digestive diseases, various infectious diseases, rheumatism, etc. Widely used in temperate areas. For example, in Taiwan, it is widely used for acute / chronic appendicitis, nephritis, gastroenteritis, diarrhea, influenza, sore throat, toothache, hepatitis, duodenal inflammation, and is said to have a protective effect on the liver. In Africa, it has been used to treat wounds, severe nausea, stomach pain, constipation, intestinal parasites, dysentery, diarrhea, and abdominal pain. Leaf juice is used for burns, conjunctivitis, otitis, and also as a hemostatic agent. Crushed soup and root dishes are said to work for malaria, and the Zulu people chew shoots to make rheumatic drugs. In China, it is used for enteritis, gonorrhea dysentery, and sore throat. The plant is crushed or decocted to treat wounds and chronic ulcers. Juices are used as eye drops in Central American islands, ulcers in Venezuela and Brazil, and blood pressure in the Andes in Bolivia. It is also used to promote diuresis, bile secretion, and antipyretic fever.
[0011]
The inventors have so much experience in using this plant extract, which is excellent in safety, for human diabetes, hyperlipidemia, atopic dermatitis, hepatitis, intractable summer ulcers in the lower limbs, etc. In particular, the effects were confirmed and the results were confirmed by animal experiments repeatedly. Therefore, various compounds contained in this plant were fractionated, and their isolation and purification were attempted, leading to the discovery of three new compounds. Is.
[0012]
[Measurement equipment]
Ultraviolet spectrum: Shimadzu spectrophotometer UV12008
Red external spectrum: Perkin-Elmer 1720X-FTIE spectrometer MS spectrum: Hitachi M-80 spectrometer NMR spectrum: Varian Mercury 300, and unity Inova-500 (solvent: CDCl 3 , CD 3 OD, and pyridine-d 5 , as internal standard On δ scale using tetramethylsilane)
[0013]
[Experiment 1]
Fraction isolation from raw materials Bidens pilosa L. var. Radiata (Japanese name Tachiawayukisendangusa) that grows naturally in Miyako Island, Okinawa Prefecture, is grown in pesticide-free in the field, and the cut ground parts are washed, cut, cooked, crushed, and dried The raw material was passed through the solution and drying process. 500 g of the raw material was extracted with 3.5 L of water three times under reflux, passed through a 600 mL Diaion HP-20 column, washed with water, and the column was eluted with 50% methanol and then methanol. Half of the eluate was adsorbed on a 70 g ODS column, methanol / water methanol concentration was gradually increased and sufficiently eluted with 50% methanol, and finally the fraction eluted with methanol was subjected to the next experiment.
[0014]
[Experimental example 2]
Reversed phase high performance liquid chromatography column: Cosmosil 5ph [5μ, 1.0 × 25 cm], column temperature 30 ° C.
Mobile phase: CH 3 CN-1% AcOH [10.5% -60%], 50 minutes, linear gradient, flow rate 2 mL / min
Detection: UV254nm
Each peak of the obtained HPLC was further purified by HPLC, the compound was identified from the analysis of various spectrum data of the isolated component and the decomposition reaction product, and the structure was determined.
[0015]
As a result of Experimental Example 2, the structures of the compounds A, B, C, A ′, B ′, and C ′ were determined. Its structural formula is shown in FIG.
[Figure 1]
Structural formula of the obtained compound
[0016]
Among them, A, B, and C are novel compounds not described in literatures, and their 1 H- and 13 C-NMR data are as shown in Table 1.
[Table 1]
1 H- and 13 C-NMR data of compounds A, B, and C
[0017]
The characteristic data other than NMR of these compounds are as follows.
[0018]
A: 1,2-dihydroxy-5 ( E) -tridecene-7,9,11-triyne-1- Ο -malony-2- Ο -β-D-glucopyranoside (15-1- Ο -malonate) .C 22 H 26 O 10 .SI-MS m / z : 451 (M + H) + , 473 (M + Na) + .
[0019]
A-methyl ester: C 23 H 28 O 10 .SI-MS m / z : 487 (M + Na) + , HR-SI-MS m / z : 487.1574 (M + Na) + , error: -0.4 mmu [ α] D + 5.1 ° ( c = 0.19, MeOH) .IR (KBr) cm -1 : 3588,3424 (OH), 2225 (C≡C), 1736 (COOR), 1077,1029 (COC) .UVλ max (MeOH) nm (logε): 329.5 (3.75), 307.0 (3.88), 289.0 (3.81), 272.0 (3.59), 257.0 (3.40), 241.0 (4.64), 234.0 (4.62), 210.5 (4.32). 1 H -NMR and 13 C-NMR signals are reasonably consistent with this structure.
[0020]
B: trideca-5,7,9,11-tetrayn-1,2-diol-1- Ο- malonyl-2- Ο- β-D-glucopyranoside (16-1- Ο- malonate) .C 22 H 24 O 10 .SI-MS m / z : 471 (M + Na) + , 487 (M + K) + .
[0021]
B-methyl ester: C 23 H 26 O 10 .SI-MS m / z: 485 (M + Na) +, HR-SI-MS m / z: 485.1421 (M + Na) +, error: -0.1 mmu [ α] D + 2.5 ° ( c = 0.10, MeOH) .IR (KBr) cm -1 : 3540,3436 (OH), 2229 (C≡C), 1729 (COOR), 1070,1035 (COC) .UVλ max (MeOH) nm: 329.0 (3.45), 308.0 (3.58), 289.0 (3.56), 273.0 (3.47), 235.5 (4.77), 225.0 (4.70), 215.0 (4.47). 1 H-NMR and 13 C-NMR The signal is reasonably consistent with this structure.
[0022]
C: tetradeca-6 ( E ) -en-8,10,12-triyn-1,3-diol-1- Ο- malonyl-3- Ο- β-D-glucopyranoside (17-3- Ο- malonate). C 23 H 28 O 10 .SI-MS m / z : 465 (M + H) + , 487 (M + Na) + , HR-SI-MS m / z : 465.1765 (M + H) + , error: 0.6 mmu [α] D -28.7 ° ( c = 0.29, MeOH) .IR (KBr) cm -1 : 3446 (OH), 2223 (C≡C), 1728 (COOH, COOR), 1077,1029 (COC). UVλ max (MeOH) nm (log ε): 329.5 (3.78), 308.0 (3.91), 289.0 (3.86), 272.5 (3.65), 242.0 (4.63), 233.0 (4.58), 210.5 (4.32).
[0023]
C-methyl ester: C 24 H 30 O 10 .SI-MS m / z : 479 (M + H) + , 501 (M + Na) + , HR-SI-MS m / z : 479.1917 (M + H) + , error: -0.2 mmu [α] D -20.2 ° ( c = 0.25, MeOH) .IR (KBr) cm -1 : 3587,3567,3523 (OH), 2223 (C≡C), 1737 (COOR) UVλ max (MeOH) nm (logε): 329.5 (3.83), 308.0 (3.97), 289.0 (3.90), 272.5 (3.70), 257.5 (2.50), 242.0 (4.63), 232.0 ( 4.61), 210.0 (4.39). The signals of 1 H-NMR and 13 C-NMR are reasonably consistent with this structure.
[0024]
[Activity evaluation]
Compounds of A, B, and C are described in Rosa P. Ubillas et al. [Plant Med. 66 , 82 (2000)] reported a significant reduction in blood glucose, Rachel L. et al. C. Pereila et al. Since [Immunopharmacology 43 , 31 (1999)] is very close in structure to the compound reported to support the anti-inflammatory effect, Bidens pilosa L. et al. It is undoubtedly one of a group of compounds that support the blood glucose lowering action and anti-inflammatory action.
[0025]
[Example 1]
Methanol was removed from each fraction of compounds A, B, and C obtained under the same conditions as in Experimental Examples 1 and 2 using a preparative high performance liquid chromatography apparatus by vacuum concentration, and the mixture was subjected to animal experiments. A total of 18 4-week-old male C3H mice were prepared for each of the control group, streptozotocin (STZ) group, and test group 4 group, and STZ 150 mg / kg body weight was given to the STZ group and test group on the first day and the next day. Internal injection. The control group and the STZ group are the standard feed, the test group (A to C) is the standard feed, and the fractions A, B and C are the standard feed, and the test group (fraction) is the last methanol-eluted fraction of Experimental Example 1 ( Methanol was removed under reduced pressure), and each was mixed and mixed freely so as to obtain an intake amount of about 30 g per kg body weight of the mouse in terms of raw material (processed dried Bidence / Pirosa). Two weeks later, blood glucose of each group was measured. The average value of each group was the control group 213, STZ group 683, test group (A) 516, test group (B) 476, test group (C) 498, test group ( Fraction) Significant difference was observed in all cases at 390 mg / dL.
[0026]
[Example 2]
Applying a cut vane soaked with 10% aqueous solution of sodium lauryl sulfate for 5 hours on each of the inner left and right upper arms of three volunteer women, causing redness, removing and wiping it, then one place is a commercial sunburn Cream for cream, 1 place is the last methanol-eluted fraction of Experimental Example 1, and the other 3 places are pasted with a cut bang soaked with the fractions of Compound A, B, and C obtained in Example 1, 24 hours later, 48 After observing 72 hours later, the commercially available sun cream gradually faded, but did not disappear until the end. However, in the methanol-eluted fraction of Experimental Example 1 and the fractions of compounds A, B, and C, both Redness disappeared in one day. That is, it showed a fairly strong anti-inflammatory property.
Claims (4)
(下記構造式A、BまたはCにおいて、「Glc」は「β-D-glucopyranosyl」(β-D-グルコピラノシル)を表す。)
A compound represented by the following structural formula A, B or C.
(In the structural formula A, B or C below, “Glc” represents “β-D-glucopyranosyl” (β-D-glucopyranosyl).)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002245569A JP4408612B2 (en) | 2002-08-26 | 2002-08-26 | New acetylene compounds |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002245569A JP4408612B2 (en) | 2002-08-26 | 2002-08-26 | New acetylene compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004083463A JP2004083463A (en) | 2004-03-18 |
| JP2004083463A5 JP2004083463A5 (en) | 2005-10-27 |
| JP4408612B2 true JP4408612B2 (en) | 2010-02-03 |
Family
ID=32053725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002245569A Expired - Lifetime JP4408612B2 (en) | 2002-08-26 | 2002-08-26 | New acetylene compounds |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4408612B2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070053998A1 (en) | 2005-09-02 | 2007-03-08 | Academia Sinica | Butanol extract of Bidens pilosa |
| US7763285B2 (en) * | 2007-02-12 | 2010-07-27 | Academia Sinica | Polyacetylenic compounds |
| JP5396895B2 (en) * | 2009-02-10 | 2014-01-22 | 株式会社武蔵野免疫研究所 | Anti-obesity agent |
| CN108553599A (en) * | 2018-05-21 | 2018-09-21 | 甄生联 | Treat the Chinese medicine preparation and formulation method of appendicitis |
| US20220257684A1 (en) | 2019-07-20 | 2022-08-18 | Academia Sinica | Anti-coccidial phytogenic formulations |
-
2002
- 2002-08-26 JP JP2002245569A patent/JP4408612B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004083463A (en) | 2004-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Diallo et al. | An ethnobotanical survey of herbal drugs of Gourma district, Mali | |
| Ngbolua | A review on the Phytochemistry and Pharmacology of Psidium guajava L.(Myrtaceae) and Future direction | |
| Sharanappa et al. | Plant profile, phytochemistry, and pharmacology of Argemone mexicana Linn. A review | |
| Costa et al. | Therapeutic potential of Kalanchoe species: flavonoids and other secondary metabolites | |
| Al Muqarrabun et al. | A review of the medicinal uses, phytochemistry and pharmacology of the genus Sapium | |
| Shifa et al. | Chemical constituents of Rumex abyssinicus roots and evaluation of its antimicrobial activities | |
| Abera et al. | Phytochemical investigation the root extract of Syzygium guineense and isolation of 2, 3, 23-trihydroxy methyl oleanate | |
| Awolola et al. | The phytochemistry and gastroprotective activities of the leaves of Ficus glumosa | |
| Ashraf et al. | Genus Gleditsia: A phytochemical and biological review (2015-2020) | |
| JP4408612B2 (en) | New acetylene compounds | |
| Msonthi et al. | Kingiside aglucone, a natural secoiridoid from unripe fruits of Strychnos spinosa | |
| Zakaria et al. | Ethnobotany, Phytochemistry and Pharmacology of Acanthus ilicifolius: A Comprehensive Review. | |
| Kumar et al. | Bryophyllum pinnatum: a review on medicinal benefits and potent bioactive molecules | |
| JP4864252B2 (en) | Anti-inflammatory plant component | |
| JP4115777B2 (en) | New compounds | |
| Durojaye et al. | Two antihyperglycaemic compounds from Globimetula braunii (Engl.) Van Tiegh (Loranthaceae) | |
| Chafamo et al. | Phytochemical investigation of the roots extracts of Terminalia brownie and isolation of dimethyl terephthalate | |
| Sikder et al. | In vitro antimicrobial screening of four reputed Bangladeshi medicinal plants | |
| Musa et al. | Isolation and Characterization of Neoduline from the Rhizome of Dolichos pachyrhizus Harm | |
| CN113429452B (en) | A mogrosic acid acylated derivative as an anti-inflammatory agent and an anti-inflammatory composition | |
| Siddiqui et al. | Chemical constituents from the stems of Morinda citrifolia Linn | |
| Kikowska et al. | Little-known Saniculeae genera: phytochemical studies and pharmaceutical activities | |
| CN116425651A (en) | A kind of preparation method of N-alkyl amides compound and its application in anti-inflammatory drug | |
| Tabrea et al. | Arctium lappa-a potential source of bioactive compounds with pharmaceutical applications. | |
| El-Din et al. | Subfamily Bombacoideae: Traditional Uses, Secondary Metabolites, Biological Activities, and Mechanistic Interpretation of the Anti-Inflammatory Activity of its species |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050825 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050825 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20050825 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20050825 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090511 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090709 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090709 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091026 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091110 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4408612 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121120 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131120 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |